3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
4
CNS
3
Sarcoma
2
Head & Neck
2
Genitourinary
2
Endocrine
2
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
66
Cisplatin
55
Radiotherapy, Intensity-Modulated
28
Carboplatin
27
Nivolumab
26
Paclitaxel
21
Magnetic Resonance Spectroscopy
21
Radiotherapy
20
Cetuximab
16
Specimen Handling
15
Docetaxel
15
Radiation
14
Gemcitabine
13
Fluorouracil
12
Biopsy
12
durvalumab
11
Platinum
11
Taxes
10
Drug Therapy
10
1,2-diaminocyclohexaneplatinum II citrate
10
Surveys and Questionnaires
9
Capecitabine
9
trametinib
8
tislelizumab
6
lenvatinib
6
dabrafenib
6
cemiplimab
6
atezolizumab
6
Radiosurgery
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
entrectinib
×
Head & Neck
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA